Updated: Lilly’s triple-G comparable with Mounjaro, first Phase 3 diabetes data suggest
更新：礼来的triple-G与穆峰达相当，首个三期糖尿病试验数据显示

Eli Lilly’s so-called triple-G reduced blood sugar levels in patients with type 2 diabetes by up to 1.9% in a late-stage trial — a similar margin as Mounjaro achieved in its pivotal diabetes study.
在一项晚期临床试验中，礼来旗下所谓的triple-G使2型糖尿病患者的血糖水平最多降低1.9%，这一降幅与穆峰达在其关键性糖尿病研究中取得的效果相近。